The Patent Trial and Appeal Board denied institution of an inter partes review of Kurin Inc.'s patent that discloses a blood sample optimization device, finding that Magnolia Medical Technologies Inc. was seeking to re-litigate the same validity issues that a jury found not to be invalid. According to the board, allowing the IPR to proceed would contradict congressional goals for AIA reviews to serve as litigation alternatives rather than forums for expanding litigation.
This summary was produced by Bloomberg Law Automation and edited by Bloomberg Law staff.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.